Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and A-alphalipoprotein Neuropathy

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with A-alphalipoprotein Neuropathy in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Demopoulos, CA; Kolovou, G; Kolovou, V; Papakonstantinou, VD; Stamatakis, G; Verouti, SN; Xanthopoulou, MN1
Chonn, A; Pritchard, PH; Yeung, CC1

Other Studies

2 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and A-alphalipoprotein Neuropathy

ArticleYear
Platelet activating factor levels and metabolism in Tangier disease: a case study.
    Lipids in health and disease, 2012, Jul-08, Volume: 11

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetyltransferases; Adenosine Diphosphate; Adult; Aged; Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Biological Assay; Blood Platelets; Coronary Artery Disease; Diacylglycerol Cholinephosphotransferase; Female; Humans; Middle Aged; Mutation; Platelet Activating Factor; Platelet Aggregation; Rabbits; Reference Values; Tangier Disease; Thrombin

2012
The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease).
    Blood, 1985, Volume: 66, Issue:6

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Humans; Hypolipoproteinemias; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Phenotype; Phospholipases A; Phospholipases A2; Platelet Activating Factor; Tangier Disease

1985